SCHEMBL4054584

SCHEMBL4054584

Nc1cccc(-c2nc3ccc(-c4ccccc4F)cc3o2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.61
KDM4E B2RXH2 9/20 0.61
RAB9A P51151 9/20 0.61
MAPT P10636 8/20 0.61
ALDH1A1 P00352 7/20 0.61
SMN1; SMN2 Q16637 7/20 0.61
HPGD P15428 6/20 0.61
VSIR Q9H7M9 2/20 0.61
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
GAA P10253 4/20 0.52
GLA P06280 2/20 0.52
NFKB1 P19838 2/20 0.51
NFKB2 Q00653 2/20 0.51
RELA Q04206 2/20 0.51
CACNA1B Q00975 1/20 0.48
APBA1 Q02410 1/20 0.48
BACE1 P56817 1/20 0.48
GPR119 Q8TDV5 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054275 0.87 VSIR (0.63) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL4054476 0.87 VSIR (0.61) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL4058059 0.85 VSIR (0.61) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL4052730 0.83 VSIR (0.59) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL4050635 0.82 VSIR (0.58) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL4060165 0.82 VSIR (0.58) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL4057255 0.82 VSIR (0.58) NPC1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL4062955 0.82 VSIR (0.56) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL6683035 0.81 NPC1 (0.70) NPC1KDM4ERAB9AMAPTALDH1A1
SCHEMBL13608507 0.81 VSIR (0.59) NPC1KDM4ERAB9AMAPTVSIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885KDM4E 496/4885RAB9A 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.